Announcement of Non-Operating Losses

Oncolys BioPharma (“Oncolys”) announces today that non-operating losses were recorded in the non-consolidated cumulative first quarter (1/1/2017 - 31/3/2017) as follows:

1. Details of non-operating losses

Due to recent fluctuations in foreign currency exchange rates, in the non-consolidated cumulative first quarter (1/1/2017 – 31/3/2017), foreign exchange losses of JPY 6,845,000 were recorded as non-operating losses. This amount, however, is calculated based on the foreign exchange rates as of the end of March 2017 therefore it is still subject to change in the future.

The announcement above will not affect Oncolys’ earnings for the fiscal year ending 31 December 2017.

Ends

About Oncolys BioPharma Inc.

Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS.

For more information, please visit http://www.oncolys.com/en/

Oncolys BioPharma Inc.
Mie Yamazaki
Investor Relations & Corporate Communications
Tel: +81 (0) 5472 1578
Email: yamazaki@oncolys.com